EU Preparing Guidance On Synthetic Oligonucleotides & Peptides
Executive Summary
Two new quality guidelines are needed to address the increase in applications for clinical trials and marketing authorizations of oligonucleotide- and peptide-based medicines, says the EU regulator.
You may also be interested in...
EMA Consults On Quality Expectations For Synthetic Peptide Medicines
A draft guideline by the European Medicines Agency aims to clarify specific considerations applicable to synthetic peptides from a quality point of view.
Oligonucleotides, Oxycodone And Osteoarthritis Among 49 US FDA Guidances
The FDA has seemingly followed the lead of the EMA by guiding ANDA sponsors on how to develop oligonucleotide drugs, a complex class of DNA or RNA molecules.
Sandoz Eyes In-House GLP-1 Development – Apart From ‘Key’ APIs
With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.